Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 434

1.

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM.

N Engl J Med. 1999 Dec 16;341(25):1874-81.

2.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team.

N Engl J Med. 2001 Aug 9;345(6):398-407.

3.

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM.

N Engl J Med. 1999 Dec 16;341(25):1865-73.

4.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
5.

Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.

Nadal D, Steiner F, Cheseaux JJ, Lazarevitch CA, Aebi C, Kind C, Rudin C.

Infection. 2000 Sep;28(5):287-96. Erratum in: Infection 2000 Nov-Dec;28(6):402.

PMID:
11073135
6.

Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.

Spector SA, Hsia K, Yong FH, Cabral S, Fenton T, Fletcher CV, McNamara J, Mofenson LM, Starr SE.

J Infect Dis. 2000 Dec;182(6):1769-73. Epub 2000 Oct 26.

PMID:
11069252
7.

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.

Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Gersten M, Kerr B, Hendricks A, Boczany B, Rosenberg M, Jung D, Spector SA, Bryson Y.

Clin Infect Dis. 1999 May;28(5):1109-18.

PMID:
10452644
8.

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team.

N Engl J Med. 2003 Sep 11;349(11):1036-46.

9.

Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.

Funk MB, Notheis G, Schuster T, Elanjkal Z, von Hentig N, Stürmer M, Linde R, Dunsch D, Königs C, Wintergerst U, Kreuz W.

Eur J Med Res. 2005 Dec 7;10(12):503-8.

PMID:
16356864
10.

Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.

Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, Starr SE, Spector SA.

J Infect Dis. 2002 May 15;185(10):1409-16. Epub 2002 Apr 30.

PMID:
11992275
11.

Efavirenz liquid formulation in human immunodeficiency virus-infected children.

Starr SE, Fletcher CV, Spector SA, Brundage RC, Yong FH, Douglas SD, Flynn PM, Kline MW; PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group.

Pediatr Infect Dis J. 2002 Jul;21(7):659-63.

PMID:
12237599
12.

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.

Seminari E, Maggiolo F, Villani P, Suter F, Pan A, Regazzi MB, Paolucci S, Baldanti F, Tinelli C, Maserati R.

J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):453-60. Erratum in: J Acquir Immune Defic Syndr 2000 Mar 1;23(3):278.

PMID:
10961606
13.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team.

N Engl J Med. 2004 Apr 29;350(18):1850-61.

14.

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team.

JAMA. 2002 Jul 10;288(2):169-80.

PMID:
12095381
15.

A trial of three antiretroviral regimens in HIV-1-infected children.

Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL; PACTG 356 Investigators.

N Engl J Med. 2004 Jun 10;350(24):2471-80.

16.

Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.

Barreiro P, Oller V, Soriano V, Nuñez M, Rodríguez-Rosado R, González-Lahoz J.

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):391-2. No abstract available.

PMID:
11317086
17.

Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.

Kline MW, Brundage RC, Fletcher CV, Schwarzwald H, Calles NR, Buss NE, Snell P, DeLora P, Eason M, Jorga K, Craig C, Duff F.

Pediatr Infect Dis J. 2001 Jul;20(7):666-71.

PMID:
11465838
18.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team.

N Engl J Med. 2002 Jun 27;346(26):2039-46.

19.

Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.

Reiser M, Salzberger B, Stiepel A, Hoetelmans R, Diehl V, Fätkenheuer G.

Eur J Med Res. 1999 Feb 25;4(2):54-8.

PMID:
10066640
20.

High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.

Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB.

AIDS. 1999 May 7;13(7):870-1. No abstract available.

PMID:
10357395

Supplemental Content

Support Center